Your Questions, Answered

Wondering if Allumia Ventures is the right partner for your needs? Let us clear up any doubts.

  • We’re not just another financial investor; we were born from Providence, one of the largest customers in the market where our portfolio companies operate. This heritage gives us unique access to and empathy for a network of stakeholders that are directly relevant to the companies we partner with. That’s why 100% of our portfolio has partnered with our LP base. How many other institutional funds can say that?

  • While our customer access is similar to a CVC, we’re an independent venture capital firm. This gives Allumia the commensurate flexibility and incentive to drive venture-class returns. We really do have the best of both worlds.

  • Yes and yes. While we’re inclined to lead rounds, we also have the flexibility to co-lead or join a syndicate. When we lead, we typically invite other trusted co-investors to partner with us in the financing. Taking board seats is important to us because it helps ensure accountability–on ourselves–post-investment. We’re with you until the end.

  • No, they don’t. In fact, one of our main goals is to connect our portfolio companies with the right stakeholder within our strategic investor base so that they can eventually become partners.

  • No, our investment in a company is completely independent from any vendor relationship with our LPs. We adhere to strict conflict of interest practices to ensure this separation. Instead, we maintain continuous engagement with our strategic investors to effectively map their top priorities to the right solution in our portfolio. We’ve found that this approach maximizes partnership success–not making vendor relationships compulsory upon an investment.

  • We focus on best-in-class commercial-stage healthcare companies that leverage technology to solve healthcare’s most pressing issues. Specifically, our investment strategy focuses on the following:

    • Sector focus: Digital Health, Tech-enabled Healthcare Services, MedTech

    • Geographical focus: United States (including ex-US companies with a majority focus in the US)

    • Commercial-stage focus: Revenue-generating (typically Series A-C)

    • Investment amount: $5-15M

    • Board participation: Prefer taking board seats

    • Lead/syndicate: Prefer to lead or co-lead but can participate in syndicate as well, depending on deal dynamics